Pharmaceutical Technology3 天
UK-based Verdiva launches with $410m and an oral GLP-1RA candidate
Financing was co-led by Forbion and General Atlantic, with participants including RA Capital Management, OrbiMed, and Lilly Asia Ventures.
clinicaltrialsarena3 天
Viking Therapeutics begins VK2735 Phase II trial for obesity treatment
Viking Therapeutics has begun a Phase II clinical trial of VK2735 aimed at treating metabolic disorders, such as obesity.
clinicaltrialsarena4 天
BIAL’s first subject completes full dose regimen in Parkinson’s treatment trial
BIAL has completed the full dose regimen for the first subject in the Phase II ACTIVATE trial of BIA 28-6156, for Parkinson's treatment.
Pharmaceutical Technology6 天
FDA grants ODD to NMD Pharma’s Charcot-Marie-Tooth disease therapy
The US FDA has granted ODD to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT).